Literature DB >> 18167110

Serum liver enzyme activities in healthy Miniature Schnauzers with and without hypertriglyceridemia.

Panagiotis G Xenoulis1, Jan S Suchodolski, Melinda D Levinski, Jörg M Steiner.   

Abstract

OBJECTIVE: To determine whether hypertriglyceridemia in healthy Miniature Schnauzers is associated with high serum liver enzyme activities.
DESIGN: Cross-sectional study. ANIMALS: 65 Miniature Schnauzers with serum triglyceride concentrations within the reference range (group 1), 20 Miniature Schnauzers with slightly high serum triglyceride concentrations (group 2), and 20 Miniature Schnauzers with moderately to severely high serum triglyceride concentrations (group 3). PROCEDURES: Questionnaires regarding each dog's medical history were completed, and serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and G-glutamyltransferase (GGT) activities were measured.
RESULTS: Median serum ALP activity was significantly higher in group 3 than in group 1 or 2 dogs, but was not significantly higher in group 2 than in group 1 dogs. Median serum ALT activity was significantly higher in group 3 than in group 1 dogs, but was not significantly different between any of the other groups. Compared with group 1 dogs, group 2 and 3 dogs were significantly more likely to have high serum ALP activity (odds ratio, 26.2 and 192.6, respectively). Group 3 dogs also were significantly more likely to have high serum ALT activity (odds ratio, 8.0), serum AST activity (odds ratio, 3.7), and serum GGT activity (odds ratio, 11.3), compared with group 1 dogs. Group 3 dogs were significantly more likely (odds ratio, 31.0) to have > or = 2 high serum liver enzyme activities than were group 1 dogs. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that moderate to severe hypertriglyceridemia was associated with high serum liver enzyme activities in Miniature Schnauzers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18167110     DOI: 10.2460/javma.232.1.63

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

1.  Glomerular Lesions in Proteinuric Miniature Schnauzer Dogs.

Authors:  E Furrow; G E Lees; C A Brown; R E Cianciolo
Journal:  Vet Pathol       Date:  2016-12-22       Impact factor: 2.221

2.  Proteinuria and lipoprotein lipase activity in Miniature Schnauzer dogs with and without hypertriglyceridemia.

Authors:  E Furrow; J Q Jaeger; V J Parker; K W Hinchcliff; S E Johnson; S J Murdoch; I H de Boer; R G Sherding; J D Brunzell
Journal:  Vet J       Date:  2016-04-20       Impact factor: 2.688

3.  Therapy of Canine Hyperlipidemia with Bezafibrate.

Authors:  V De Marco; K S M Noronha; T C Casado; E R Nakandakare; J C Florio; E Z Santos; C Gilor
Journal:  J Vet Intern Med       Date:  2017-04-06       Impact factor: 3.333

4.  Clinical Consequences of Hypertriglyceridemia-Associated Proteinuria in Miniature Schnauzers.

Authors:  R E Smith; J L Granick; C D Stauthammer; D J Polzin; D A Heinrich; E Furrow
Journal:  J Vet Intern Med       Date:  2017-09-23       Impact factor: 3.333

5.  Novel lipoprotein density profiling in healthy dogs of various breeds, healthy Miniature Schnauzers, and Miniature Schnauzers with hyperlipidemia.

Authors:  Panagiotis G Xenoulis; Paul J Cammarata; Rosemary L Walzem; Ronald D Macfarlane; Jan S Suchodolski; Jörg M Steiner
Journal:  BMC Vet Res       Date:  2013-03-08       Impact factor: 2.741

6.  Starch sources influence lipidaemia of diabetic dogs.

Authors:  Fabio Alves Teixeira; Daniela Pedrosa Machado; Juliana Toloi Jeremias; Mariana Ramos Queiroz; Cristiana Ferreira Fonseca Pontieri; Marcio Antonio Brunetto
Journal:  BMC Vet Res       Date:  2020-01-03       Impact factor: 2.741

7.  Effect of a low-fat diet on serum triglyceride and cholesterol concentrations and lipoprotein profiles in Miniature Schnauzers with hypertriglyceridemia.

Authors:  Panagiotis G Xenoulis; Paul J Cammarata; Rosemary L Walzem; Jan S Suchodolski; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2020-10-06       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.